Role Description

This is a full-time, on-site role for an experienced R&D manager. The VP R&D will be responsible for all R&D activities, including strategy and budget, ongoing system design improvement (HW/SW/FW), and manufacturing, as well as design and development of Gen. 2 systems. The VP R&D will provide instruction and oversight to a highly experienced 4-person engineering team, and will manage external manufacturers and suppliers in the US and EU.

The VP R&D will work closely with other management personnel and will support the clinical trial operation as well as other various company activities, including travel to clinical cases if required.

Qualifications

• Long-term experience in R&D leadership roles for multidisciplinary, FDA-regulated implantable or complex medical devices 
• Strong project management skills and experience in leading product development
• Effective in team, time, and budget management
• Ability to manage and lead cross-functional teams
• Experience in supporting clinical studies for medical device
• Understanding and familiarity with applicable regulatory standards and guidelines for FDA-regulated devices
• Excellent communicator with keen attention to detail 
• Excellent verbal and written Hebrew and English
• BSc/MSc or higher in a relevant field (e.g. Biomedical Engineering, Electrical Engineering, etc.). MBA or similar is an advantage 
• Can-do attitude. Team player. Problem solver. Seeking to make a difference and impact the world for the better

About Discure Technologies

Discure is developing a minimally invasive, implantable device, with a unique bioelectric technology, designed to treat and reverse degenerative disc disease (DDD), reducing pain and restoring function to patients. Unlike existing treatments, that are symptom-focused, the Discure System is a disease-modifying solution, designed to reduce the use of opioids and the need for invasive back surgery.

The company has received FDA Breakthrough Device Designation and was named “Best New Technology in Spine Care in 2021” at the North American Spine Society (NASS).

The company raised over $12m to date, and completed a Series-A financing in January 2024. Investors in the company include Johnson & Johnson, Bold Capital, UVM Health Ventures, and VTC Ventures. First-in-human studies are to be initiated in March 2024. 

Offices are located in Herzliya and will move to the Petach-Tikva area in 2024.